Protection of rhesus macaques from infection with SIVMAC using a formalin inactivated whole virus preparation.

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Protection of rhesus macaques from infection with SIVMAC using a formalin inactivated whole virus preparation.

Symp Nonhum Primate Models AIDS. 1990 Nov 28-30;8:52 (abstract no. 36). Unique Identifier : AIDSLINE PRIM8/900036
Cranage MP; Cook N; Thompson A; Greenaway PJ; Baskerville A; Public Health Laboratory Service Centre for Applied Microbiology; and Research, Porton Down, Salisbury SP4 OJG, United Kingdom

Abstract: Eight rhesus macaques were inoculated with formalin inactivated SIVMAC251 (32H isolate) prepared from cell free supernatant of infected C8166 cells by gel filtration chromatography. Each animal received a total of four intramuscular inoculations of 500 mug administered in threonyl muramyl dipeptide adjuvant (kindly provided by Syntex Corporation). Four animals received a primary inoculation, two boosts at monthly intervals and a final boost two months later and were then challenged intravenously, together with two control animals, two weeks later with 10 MID50 of homologous virus. Virus was isolated from control animals at 12, 27, 40 and 55 days (to date) post challenge, whereas no virus was recovered from the vaccinated group. These results were confirmed by PCR analysis of DNA from monkey PBL's (personal communication P. Kitchin, NIBSC). A further four animals were given a primary vaccination, two monthly boosts and a final boost four months later and were then challenged two weeks later with 10 MID50 of SIVDELTAB670 (kindly provided by Dr Murphey Corb). Data from the heterologous challenge group are not yet available at the time of writing. All vaccinated animals made strong humoral immune responses. Preliminary data on the analysis of the protective immune response will be presented.

Keywords: Acetylmuramyl-Alanyl-Isoglutamine/IMMUNOLOGY Animal Antibodies, Viral/BIOSYNTHESIS Cells, Cultured Chromatography, Gel DNA, Viral/ANALYSIS Formaldehyde/*PHARMACOLOGY Leukocytes, Mononuclear/MICROBIOLOGY Macaca mulatta Polymerase Chain Reaction Simian Acquired Immunodeficiency Syndrome/*PREVENTION & CONTROL SIV/DRUG EFFECTS/GENETICS/*IMMUNOLOGY Vaccination Vaccines, Inactivated *Viral Vaccines ABSTRACT
910730
M9170958

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .